- Home
- MAT vs RYTM Comparison
MAT vs RYTM Comparison
Compare MAT & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAT
- RYTM
- Stock Information
- Founded
- MAT 1945
- RYTM 2008
- Country
- MAT United States
- RYTM United States
- Employees
- MAT 34000
- RYTM N/A
- Industry
- MAT Recreational Games/Products/Toys
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- MAT Consumer Discretionary
- RYTM Health Care
- Exchange
- MAT Nasdaq
- RYTM Nasdaq
- Market Cap
- MAT 5.8B
- RYTM 6.4B
- IPO Year
- MAT N/A
- RYTM 2017
- Fundamental
- Price
- MAT $18.27
- RYTM $109.77
- Analyst Decision
- MAT Strong Buy
- RYTM Strong Buy
- Analyst Count
- MAT 8
- RYTM 13
- Target Price
- MAT $25.38
- RYTM $110.31
- AVG Volume (30 Days)
- MAT 3.8M
- RYTM 618.1K
- Earning Date
- MAT 10-21-2025
- RYTM 11-04-2025
- Dividend Yield
- MAT N/A
- RYTM N/A
- EPS Growth
- MAT 74.53
- RYTM N/A
- EPS
- MAT 1.58
- RYTM N/A
- Revenue
- MAT $5,335,500,000.00
- RYTM $156,287,000.00
- Revenue This Year
- MAT $2.37
- RYTM $46.14
- Revenue Next Year
- MAT $2.89
- RYTM $63.37
- P/E Ratio
- MAT $11.45
- RYTM N/A
- Revenue Growth
- MAT N/A
- RYTM 53.55
- 52 Week Low
- MAT $13.95
- RYTM $45.91
- 52 Week High
- MAT $22.07
- RYTM $113.91
- Technical
- Relative Strength Index (RSI)
- MAT 56.73
- RYTM 69.10
- Support Level
- MAT $16.95
- RYTM $97.97
- Resistance Level
- MAT $18.25
- RYTM $113.91
- Average True Range (ATR)
- MAT 0.60
- RYTM 3.60
- MACD
- MAT 0.09
- RYTM 1.19
- Stochastic Oscillator
- MAT 64.98
- RYTM 78.93
About MAT Mattel Inc.
Mattel manufactures and markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, hand-held and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Nearly 60% of its net sales were generated from North America in 2024, with the remainder stemming from international markets.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.